We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

27 hedge funds and large institutions have $5.16M invested in Moleculin Biotech in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 2

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

42% more funds holding

Funds holding: 19 → 27 (+8)

0% more ownership

Funds ownership: 0% → 0% (+0%)

3% less capital invested

Capital invested by funds: $5.31M → $5.16M (-$147K)

Holders
27
Holders Change
+8
Holders Change %
+42.11%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
5
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$245K
2
Renaissance Technologies
Renaissance Technologies
New York
+$116K
3
Jane Street
Jane Street
New York
+$43.9K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$41.3K
5
ARTA
A.R.T. Advisors
New York
+$33.6K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$87.8K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$20K
3
BlackRock
BlackRock
New York
-$7.75K
4
ACS
Archford Capital Strategies
Illinois
-$4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.89M -$87.8K -34 -3%
Renaissance Technologies
2
Renaissance Technologies
New York
$1.04M +$116K +45 +12%
Millennium Management
3
Millennium Management
New York
$237K +$245K +95 New
WIC
4
Whitegate Investment Counselors
New Hampshire
$168K – – –
Truist Financial
5
Truist Financial
North Carolina
$155K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$140K – – –
BlackRock
7
BlackRock
New York
$118K -$7.75K -3 -6%
Bank of New York Mellon
8
Bank of New York Mellon
New York
$78K +$41.3K +16 +107%
Northern Trust
9
Northern Trust
Illinois
$74K +$20.7K +8 +38%
Jane Street
10
Jane Street
New York
$42K +$43.9K +17 New
Morgan Stanley
11
Morgan Stanley
New York
$39K +$5.17K +2 +14%
ARTA
12
A.R.T. Advisors
New York
$31K +$33.6K +13 New
RJFSA
13
Raymond James Financial Services Advisors
Florida
$22K – – –
HF
14
HRT Financial
New York
$22K +$23.3K +9 New
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$19K – – –
Commonwealth Equity Services
16
Commonwealth Equity Services
Massachusetts
$13K +$2.58K +1 +25%
UBS Group
17
UBS Group
Switzerland
$12K +$12.9K +5 New
LNWWM
18
Laird Norton Wetherby Wealth Management
California
$11K – – –
CF
19
Centaurus Financial
California
$11K +$10.3K +4 New
SIM
20
Sonora Investment Management
Arizona
$11K +$10.3K +4 New
Victory Capital Management
21
Victory Capital Management
Texas
$8K +$7.75K +3 New
CTB
22
Country Trust Bank
Illinois
$3K – – –
PFGIA
23
Patriot Financial Group Insurance Agency
Massachusetts
$3K – – –
Wells Fargo
24
Wells Fargo
California
$3K – – –
Rockefeller Capital Management
25
Rockefeller Capital Management
New York
$3K +$2.58K +1 New
1
2

MBRX Hedge Fund Activity: Q3 2019 in Review

27 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2019, worth a combined $5.16M — down 2.8% from $5.31M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new MBRX positions and 2 closed out — a net gain of 8 holders — while 5 added to existing stakes and 2 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $245K. The largest seller was Vanguard Group, cutting an estimated $87.8K.

  • 27 institutional investors held Moleculin Biotech (MBRX) as of Q3 2019, up from 19 in Q2 2019.
  • Funds reported $5.16M of Moleculin Biotech stock for Q3 2019, down 2.8% quarter-over-quarter.
  • 10 funds opened new Moleculin Biotech positions in Q3 2019 and 2 closed out, a net change of +8 holders.
  • The largest Moleculin Biotech buyer in Q3 2019 was Millennium Management, an estimated $245K added.
  • The largest Moleculin Biotech seller in Q3 2019 was Vanguard Group, an estimated $87.8K sold.

Based on aggregated 13F filings for Q3 2019.